Mycophenolate Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases. GNH USA supplies Mycophenolate Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil Accord is an antimetabolite immunosuppressant used in conditions where immune modulation is required. - Organ transplant rejection: helps prevent graft rejection by suppressing lymphocyte proliferation. - Kidney transplant: supports long‑term graft survival through immune inhibition. - Autoimmune disease (e.g., lupus nephritis): reduces disease activity by limiting immune‑mediated tissue damage.

Adverse reactions may occur with Mycophenolate Mofetil Accord.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may affect hydration. - Headache: transient cranial discomfort. - Increased susceptibility to infections: higher frequency of upper‑respiratory infections.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia requiring monitoring. - Severe infections: opportunistic bacterial, viral, or fungal infections. - Liver toxicity: elevated transaminases or hepatitis.

Patients receiving Mycophenolate Mofetil Accord should follow specific safety measures. - Monitor blood counts: regular CBC to detect bone‑marrow effects. - Assess renal function: adjust therapy if kidney impairment is present. - Contraindicated in pregnancy: drug is category X and can cause fetal harm. - Use effective contraception: both male and female patients must employ reliable birth control. - Adjust dose in hepatic impairment: consider reduced exposure in liver disease. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil Accord can interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression increases risk of cytopenias. - Live vaccines: heightened risk of vaccine‑derived infection due to immunosuppression. - Antacids containing aluminum or magnesium: may reduce mycophenolate absorption.

Moderate Interactions (Monitor Closely): - Cyclosporine: can raise mycophenolate plasma levels, necessitating dose adjustment. - Tacrolimus: similar effect on mycophenolate exposure, requiring monitoring. - Warfarin: may alter INR, so coagulation parameters should be checked regularly.